

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/811,838-Conf. #3057
				Filing Date	March 30, 2004
				First Named Inventor	Theoharis C. THEOHARIDES
				Art Unit	1617
				Examiner Name	S. Wang
Sheet	1	of	4	Attorney Docket Number	2003133.00125US10

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-7,115,278	10-03-2006	Theoharides	
	AB*	US-6,984,667	01-10-2006	Theoharides	
	AC*	US-2007/0141187	06-21-2007	Theoharides	
	AD*	US-2005/0220909	10-06-2005	Theoharides	
	AE*	US-5,876,744	03-02-1999	Della Valle et al.	
	AF*	US-6,162,787	12-19-2000	Sorgente et al.	
	AG*	US-5,972,999	10-26-1999	Murad	
	AH*	US-2006/0128655	06-15-2006	Falk et al.	
	AI*	US-6,492,429	12-10-2002	Graus et al.	
	AJ*	US-4,265,823	05-05-1981	Nobile	
	AK*	US-2002/0150605	10-17-2002	Yui et al.	
	AL*	US-2004/0024016	02-05-2004	Sugamata	
	AM*	US-2001/0009680	07-26-2001	Rang et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-1998/33494	08-06-1998	Kosbab		
	BB	WO-2000/78320	12-28-2000	Joint Juice Inc.		
	BC	IT-1290440	09-25-1998	TRABUCCHI EMILIO		
	BD	GB-2105193	09-12-1984	Glaxo Group Ltd.		
	BE	EP-0426479	05-08-1991	McNeil-PPC, Inc.		
	BF	WO-9721434	06-19-1997	Florio		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/811,838-Conf. #3057
				Filing Date	March 30, 2004
				First Named Inventor	Theoharis C. THEOHARIDES
				Art Unit	1617
				Examiner Name	S. Wang
Sheet	2	of	4	Attorney Docket Number	2003133.00125US10

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	International Search Report and Written Opinion, International Patent Application No. PCT/US08/86059, mailed 26 January 2009 (7 pages)	
	CB	Russell, A.L. and McCarty, M.F. "Glucosamine for migraine prophylaxis?" Medical Hypotheses, 55(3): 195-198 (2000)	
	CC	Matsuda, K. et al., "Inhibitory Effects of Sialic-Acid- or N-Acetylglucosamine-Specific Lectins on Histamine Release Induced by Compound 48/80, Bradykinin and a Polyethylenimine in Rat Peritoneal Mast Cells," Jpn. J. Pharmacol., 64: 1-8 (1994)	
	CD	Trichopoulou, A. et al., "Cancer and Mediterranean Dietary Traditions," Cancer Epidemiology, Biomarkers, & Prevention, Vol. 9: 869-873 (Sept. 2000)	
	CE	Theoharides, T.C., "The Mast Cell: A Neuroimmunoendocrine Master Player," Int. J. Tiss. Reac. XVIII(1), 1-21 (1996)	
	CF	Theoharides, T.C., "Histamine2 (H2)-Receptor Antagonists in the Treatment of Urticaria," Drugs 37: 345-355 (1989)	
	CG	Theoharides, T. "Mast Cells and Migraines," Brief Proposal, pp: 627-675 (1983)	
	CH	Morrow, J. et al., "Identification of Skin as a Major Site of Prostaglandin D2 Release Following Oral Administration of Niacin in Human," J. Invest. Derm., Vol. 98(5): 812-815 (1992)	
	CI	Weston, A. et al., "Terminal Ileal Mucosal Mast Cells In Irritable Bowel Syndrome," Dig. Diseases and Sci., Vol. 38(9): 1590-1595 (Sept. 1993)	
	CJ	Shapiro, G. et al., "Cromolyn Sodium: A Review," Pharmacotherapy, Vol. 5(3): 156-170 (May/June 1985)	
	CK	Database WPI: 2001-358435 - XP002221703, "Compositions comprising hyaluronic acid and flavonoids," (2 pages)	
	CL	International Search Report issued for PCT/US02/00476, dated December 16, 2002 (6 pages)	
	CM	Parodi et al., Arch. Psicol. Neurol. Psichiatr. Vol. 49(3): 299-303 (1988)	
	CN	Split et al., Headache, Vol. 24(30): 147-149 (1984)	
	CO	Unlisted Drugs, Vol. 20(11): 167 (November 1968)	
	CP	Koblenzer, C.S. "Neurotic excoriations and dermatitis artefacta," Dermatologic Clinics, Vol. 14(3): 447-455 (July 1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/811,838-Conf. #3057
				Filing Date	March 30, 2004
				First Named Inventor	Theoharis C. THEOHARIDES
				Art Unit	1617
				Examiner Name	S. Wang
Sheet	3	of	4	Attorney Docket Number	2003133.00125US10

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CQ	Tauberg, J. et al., "Stress-induced urticaria associated with local anesthetic administration," Anesthesia Progress, Vol. 30(6): 199-200 (1983)		
	CR	Theoharides, T.C. "Mast Cells: The Immune Gate To The Brain," Life Sciences, Vol. 46: 607-617 (1990)		
	CS	Lambracht-Hall, M. et al., "Serotonin Release From Rat Brain Mast Cells," Neuroscience, Vol. 39(1) 199-207 (1990)		
	CT	Dimitriadou, V. et al., "HISTOCHEMICAL AND ULTRASTRUCTURAL CHARACTERISTICS OF RAT BRAIN PERIVASCULAR MAST CELLS STIMULATED WITH COMPOUND 48/80 AND CARBACHOL, Neuroscience, Vol. 39(1): 209-224 (1990)		
	CU	Pearce, F.L. "Mast cell heterogeneity," TIPS: 165-167 (April 1983)		
	CV	Theoharides, T.C. and Douglas, W.W. "SOMATOSTATIN INDUCES HISTAMINE SECRETION FROM RAT PERITONEAL MAST CELLS," Endocrinology, Vol. 102(5): 1637-1640 (Nov. 7, 1977)		
	CW	Sundaram, K. et al., "Antagonists of luteinizing hormone releasing hormone bind to rat mast cells and induce histamine release," Agents and Actions, Vol. 25(3/4): 307-313 (1988)		
	CX	Prior, A. and Read, N.W. "Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5HT ₃ receptor antagonist, in patients with irritable bowel syndrome (IBS)," Brit. Soc. of Gastroent., A1174 (1 page)		
	CY	Mathias, J. et al., "Debilitating 'Functional' Bowel Disease Controlled by Leuprolide Acetate, Gonadotropin-Releasing Hormone (GnRH) Analog," Digestive Diseases and Sciences, Vol. 34(5): 761-766 (May 1989)		
	CZ	Read, N.W. "Irritable bowel syndrome (IBS)--definition and pathophysiology," Vol. 130: 7-13 (1987)		
	CA1	Stefanini, G.F. et al., "Oral disodium cromoglycate treatment on irritable bowel syndrome: An open study on 101 subjects with diarrheic type," Vol. 87: 55-57 (1992)		
	CB1	International Search Report issued for PCT/US95/01392, dated May 31, 1995 (4 pages)		
	CC1	Hendriks, J. et al., "Flavonoids Influence Monocytic CTPase Activity and Are Protective In Experimental Allergic Encephalitis," J. Exp. Med., Vol. 200(12): 1667-1672 (2004)		
	CD1	Mezzapesa, D. et al., "Glatiramer acetate in multiple sclerosis," Expert Rev. Neurotherapeutics (5)4: 451-458 (2005)		
	CE1	Gupta, E. et al., "Lovastatin and Extended-Release Niacin Combination Product: The First Drug Combination for the Management of Hyperlipidemia," Heart Disease, Vol. 4, 124-137 (2002)		
	CF1	Owens, M.J. and Nemeroff, C.B., "Physiology and Pharmacology of Corticotropin-releasing Factor," Pharmacological Reviews, Vol. 43(4): 425-615 (1991)		
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/811,838-Conf. #3057
				Filing Date	March 30, 2004
				First Named Inventor	Theoharis C. THEOHARIDES
				Art Unit	1617
				Examiner Name	S. Wang
Sheet	4	of	4	Attorney Docket Number	2003133.00125US10

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CH1	Devlin, Thomas (ed): Textbook of Biochemistry with Clinical Correlations, 2nd Edition: Ch. 8.5-8.6, 345-351 (1982)	
	CI1	Simopoulos, A.P., Visioli F. (eds): Mediterranean Diets. World Rev. Nutr. Diet. Basel, Karger, Vol. 87: 56-77 (2000)	
	CJ1	Urade, Y. et al., "The Major Source of Endogenous Prostaglandin D2 Production is Likely Antigen-Presenting Cells," J. Immunol., 143(9): 2982-2989 (Nov. 1, 1989)	
	CK1	Lidor, C. et al., "Osteoporosis as the Sole Presentation of Bone Marrow Mastocytosis," J. Bone Min Res., Vol. 5(8): 871-876 (1990)	
	CL1	Shoskes, D., et al., "Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial," Urology, 54(6): 960-963 (1999)	
	CM1	Seibold, J. et al., "Dermal Mast Cell Degranulation in Systemic Sclerosis," Arth. and Rheuma., Vol. 33(11): 1702-1709 (Nov. 1990)	
	CN1	Rockoff, S.D. and Armstrong, J.D. "Parathyroid Hormone as a Stimulus to Mast Cell Accumulation In Bone," Calc. Tiss. Res., 5: 49-55 (1970)	
	CO1	Morrow, J.D., et al., "Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid," Prostaglandins, Vol. 38(2): 263-274 (1989)	
	CP1	Boushey, R. et al., "Adrenal Cortical Carcinoma," Curr. Treatment Op. Oncol., 2: 355-364 (2001)	
	CQ1	Chines, A. et al., "Systemic Mastocytosis Presenting as Osteoporosis: A Clinical and Histomorphometric Study," J. Clin. Endocrinol. and Metab., Vol. 72(1): 140-144 (1991)	
	CR1	Singleton, V.L. and Rossi, Jr., Joseph, "Colorimetry and Total Phenolics With Phosphomolybdic-Phosphotungstic Acid Reagents," Phenolics Determination, pp. 144-158	
	CS1	Dr. Duke; PHYTOCHEMICAL AND ETHNOBOTANICAL DATABASES; CHEMICALS IN: OLEA EUROPAEA SUBSPo EUROPAEA (OLEACEAE) -- OLIVE; URL / www.ars-grin.gov/cgi-bin/duke/farmacy2.pl>, pages 1-5; 2006	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.